Stocks · News reference
UBS has lowered its price target for BioNTech SE from $135 to $125 while maintaining a "Buy" rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a venture capital fund formed by the University of Pennsylvania and BioNTech SE, has made its inaugural investment in Emvena Therapeutics.
BioNTech is facing reports of internal workplace culture concerns, including allegations of sexism and complaints from the works council regarding toxic work environments.